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Abstract
DNA vaccination can elicit both humoral and cellular immune responses and can confer protection
against several pathogens. However, DNA vaccines expressing the envelope (Env) protein of human
immunodeficiency virus (HIV) have been relatively ineffective at generating high titer, long-lasting,
neutralizing antibodies in a variety of animal models. In this study, we report that fusion of Env and
the complement component, C3d, in a DNA vaccine, enhances the titers of antibody to Env. Plasmids
were generated that expressed a secreted form of Env (sgp120) from three isolates of HIV and these
same forms fused to three tandem copies of the murine homologue of C3d (sgp120-3C3d). Analyses
of titers and avidity maturation of the raised antibody indicated that immunizations with each of the
sgp120-3C3d-expressing DNAs accelerated both the onset and the avidity maturation of antibody to
Env.
INTRODUCTION
Human immunodeficiency virus (HIV), the etiologic agent of AIDS, has become the major
cause of death in individuals 25 to 44 years of age in the United States.1 Nineteen million
people have died worldwide since the first cases were identified in 1981 and the total number
of people living with HIV/AIDS is currently estimated at 35 million.1 At the present rate, HIV
is spreading faster in the human population than any infectious agent in the last 100 years.
Despite the effectiveness of the current highly active antiretroviral therapy (HAART) drug
cocktails in developed countries, a vaccine against HIV is the best method to combat the
worldwide AIDS pandemic.
DNA vaccination has become the fastest growing field in vaccine technology (for reviews, see
2-4). These genetic vaccines consist of eukaryotic expression plasmids that are inoculated into
target cells and translated into proteins.2 DNA vaccines are comparatively easy to develop and
manufacture, and are likely to not require a cold chain for worldwide distribution. In animal
models, DNA vaccination induces protective immunity against a variety of pathogens
including influenza, herpes simplex, rabies, malaria, and measles.3,4 These studies have
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demonstrated that DNA vaccination effectively induces both humoral and cellular immune
response to immunogens from diverse infectious agents. However, DNA immunizations have
been less successful at generating neutralizing antibodies against HIV-1.5 Unlike most
immunogens, multiple DNA immunizations are required to elicit even modest titers of
neutralizing antibody to the HIV envelope (Env) glycoprotein.6-13 In addition, the antibody
responses raised by DNA vaccination, like those to Env (gp120) subunit immunizations, are
transient, rising and falling with each successive immunization.14-16 Studies using simian
immunodeficiency virus (SIV) in a macaque animal model demonstrated that DNA
immunization elicited neutralizing antibody that was only 10% that of SIV-infected monkeys.
10 In natural infections, in HIV-infected patients, or in experimentally SIV-infected rhesus
macaques, specific antibodies require 6 to 8 months to achieve avidity maturation. This
maturation is associated with the appearance of neutralizing antibody.17 The time required for
maturation of envelope-specific antibodies parallels the time necessary for the development of
protective immunity to experimental challenge with SIV.17 Also, protection to virus challenge
could be associated with a combination of antibody properties that includes high titer to Env,
high avidity, and in vitro neutralization of the challenge virus. Therefore, we sought to increase
the efficacy of DNA vaccines expressing HIV Env using a component of the innate immune
system, C3d, to enhance both the levels of antibody and the avidity maturation of the elicited
antibody.
In prior studies in mice, the fusion of two or three copies of C3d to a model antigen, hen egg
lysozyme (HEL), increased the efficiency of immunizations by more than 1000-fold.18 In the
human immune system, C3d is one of the final degradation products of the third complement
protein, C3. One consequence of complement activation is the covalent attachment of the C3d
to antigen. C3d in turn binds to CD21 on B lymphocytes, a molecule with B cell stimulatory
functions that amplify B lymphocyte activation.18 Recently, we examined whether a DNA
vaccine expressing a fusion of hemagglutinin (HA) from influenza virus and the C3d
component of complement could achieve an earlier and more efficient protective immune
response.19 Our results demonstrated that mice vaccinated with DNA expressing a secreted
HA fused to three copies of C3d (sHA-3C3d) generated antibody that underwent more rapid
avidity maturation than antibody generated by secreted or transmembrane forms of HA. This
resulted in more rapid appearance of hemagglutination inhibition (HI) activity and protective
immunity.19
In this study, we used a similar approach by fusing three copies of murine C3d to the carboxyl
terminus of the HIV Env gp120 subunit. Using DNA vaccination, BALB/c mice were
inoculated and assayed for enhanced immune responses. The fusion constructs induced higher
antibody responses to Env and a faster onset of avidity maturation than did the respective wild-
type gp120 sequences. These results suggest that the efficacy of DNA vaccines for raising
antibody can be significantly improved by fusing proteins with C3d.
MATERIALS AND METHODS
Plasmid DNA
pGA, a eukaryotic expression vector, has been described previously.19 Briefly, the vector was
constructed to contain the cytomegalovirus immediate-early promoter (CMV-IE) plus intron
A (IA) for initiating transcription of eukaryotic inserts and the bovine growth hormone
polyadenylation signal [BGH poly(A)] for termination of transcription (Fig. 1). The vector
contains the Col E1 origin of replication for prokaryotic replication and the kanamycin
resistance gene (Kanr) for selection in antibiotic media.
HIV envelope sequences from the isolates, ADA, IIIB, and 89.6 encoding almost the entire
gp120 region (Fig. 1A) and C3d sequences were cloned into the pGA vaccine vector using
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unique restriction endonuclease sites (Fig. 1B). The gp120 segment encodes a region from
amino acid 32 to 465 and ended with the amino acid sequence VAPTRA. The first 32 amino
acids were deleted from the N-terminus of each sgp120 and replaced with a leader sequenced
from the trypsin plasminogen activator (tpA). The vectors expressing sgp120-C3d fusion
proteins were generated by cloning three tandem repeats of the mouse homologue of C3d in
frame with the sgp120-expressing DNA. The construct design was based upon Dempsey et al.
18 Linkers composed of two repeats of four glycines and a serine {(G4S)2} were fused at the
junctures of ENV and C3d and between each C3d repeat. Potential proteolytic cleavage sites
between the junction of ENV and C3d and the junctions of 3C3d were mutated by ligating
BamHI and BglII restriction endonuclease sites to mutate an Arg codon to a Gly codon.19
The plasmids were amplified in Escherichia coli strain DH5a, purified using anion-exchange
resin columns (Qiagen, Valencia, CA) and stored at 220° in dH2O. Plasmids were verified by
appropriate restriction enzyme digestion and gel electrophoresis. Purity of DNA preparations
was determined by optical density reading at 260 and 280 nm.
Mice and DNA immunizations
Six- to 8-week-old BALB/c mice (Harlan Sprague Dawley, Indianapolis, IN) were used for
inoculations. Mice, housed in microisolator units and allowed free access to food and water,
were cared for under USDA guidelines for laboratory animals. Mice were anesthetized with
0.03-0.04 ml of a mixture of 5 ml ketamine-HCl (100 mg/ml) and 1 ml xylazine (20 mg/ml).
Gene gun immunizations were performed on shaved abdominal skin using the hand-held
Accell® gene delivery system as described previously.20-22 Mice were immunized with two
gene gun doses containing 0.5 ?g of DNA/0.5 mg of approximately 1-?m gold beads (DeGussa-
Huls Corp., Ridgefield Park, NJ) at a helium pressure setting of 400 psi.
Transfections and expression analysis
The human embryonic kidney cell line, 293T (5 × 105 cells/transfection), was transfected with
2 ?g of DNA using 12% lipofectamine according to the manufacturer’s (Life Technologies,
Grand Island, NY) guidelines. Supernatants were collected and stored at 220°. Cell lysates
were collected in 300 ?l of RIPA lysis buffer [0.05 M Tris-HCl, pH 8.0, 0.1% sodium dodecyl
sulfate (SDS), 1.0% Triton X-100, 2 mM phenylmethylsulfonyl fluoride (PMSF), 0.15 M
NaCl] and stored at 220°. Quantitative antigen capture enzyme-linked immunosorbent assays
(ELISAs) were conducted as previously described.23
For Western hybridization analysis, 15 ?l of supernatant or cell lysate was diluted 1:2 in SDS
sample buffer (Bio-Rad, Hercules, CA) and loaded onto a 10% polyacrylamide/SDS gel. The
resolved proteins were transferred onto a nitrocellulose membrane (Bio-Rad, Hercules, CA)
and incubated with a 1:1000 dilution of polyclonal human HIV-infected patient antisera in
phosphate-buffered saline (PBS) containing 0.1% Tween 20 and 1% nonfat dry milk. After
extensive washing, bound human antibodies were detected using a 1:2000 dilution of
horseradish peroxidase-conjugated goat anti-human antiserum and enhanced
chemiluminescence (Amersham, Buckinghamshire, UK).
ELISA and avidity assays
An end point ELISA was performed to assess the titers of anti-Env immunoglobulin G (IgG)
in immune serum using purified HIV-1-IIIB gp120 Chinese hamster ovary (CHO)-expressed
protein (Intracell) to coat plates as described.16 Alternatively, plates were coated with sheep
anti-Env antibody (International Enzymes Inc., Fallbrook, CA) and used to capture sgp120
produced in 293T cells that were transiently transfected with sgp120 expression vectors. Mouse
serum from vaccinated mice was allowed to bind and subsequently detected by anti-mouse
IgG conjugated to horseradish peroxidase. End point titers were considered positive that were
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2-fold higher than background. Avidity ELISAs were performed similarly to serum antibody
determination ELISAs up to the addition of samples and standards. Samples were diluted to
give similar concentrations of specific IgG by OD. Plates were washed three times with 0.05%
PBS-Tween 20. Different concentrations of the chaotropic agent, sodium thiocyanate (NaSCN)
in PBS, were then added (0, 1, 1.5, 2, 2.5, and 3 M NaSCN). Plates were allowed to stand at
room temperature for 15 min and then washed six times with PBS-Tween 20. Subsequent steps
were performed similarly to the serum antibody determination ELISA. Percent of initial IgG
was calculated as a percent of the initial OD. All assays were done in triplicate.
Neutralizing antibody assays
Antibody-mediated neutralization of HIV-1 IIIB and 89.6 was measured in an MT-2 cell-
killing assay as described previously.23 Briefly, cell-free virus (50 ?l containing 108
TCID50 of virus) was added to multiple dilutions of serum samples in 100 ?l of growth medium
in triplicate wells of 96-well microtiter plates coated with poly-L-lysine and incubated at 37°
for 1 h before MT-2 cells were added (105 cells in 100 ?l added per well). Cell densities were
reduced and the medium was replaced after 3 days of incubation when necessary.
Neutralization was measured by staining viable cells with Finter’s neutral red when cytopathic
effects in control wells were >70% but less than 100%. Percentage protection was determined
by calculating the difference in absorption (A540) between test wells (cells + virus) and dividing
this result by the difference in absorption between cell control wells (cells only) and virus
control wells (virus only). Neutralizing titers are expressed as the reciprocal of the plasma
dilution required to protect at least 50% of cells from virus-induced killing.
RESULTS
Expression of plasmids
The Env vaccine plasmids were constructed using the previously described pGA vector to
express a secreted form of Env (sgp120) or a C3d fusion of the secreted form of Env
(sgp120-3C3d) (Fig. 1A). The Env gene was cloned from one of three HIV isolates, ADA,
IIIB, and 89.6. The molecularly cloned gp120 region represented the entire surface domain of
Env, but excluded the oligomerization and transmembrane domains and the cytoplasmic
regions (Fig. 1B). The sgp120-3C3d fusion protein was generated by cloning three tandem
repeats of the mouse homologue of C3d18 in frame with the sgp120 gene (Fig. 1B). The
proteolytic cleavage sites, found at the junction between each C3d molecule as well as the
junction between the gp120 protein and the first C3d coding region, were destroyed by
mutagenesis.
Env was expressed at overall similar levels by plasmids containing either the secreted form of
the antigen, but at a 2- to 4-fold lower level by the sgp120-C3d-expressing plasmids (Table 1).
Human 293T cells were transiently transfected with 2 ?g of plasmid and both supernatants and
cell lysates were assayed for gp120 using an antigen capture ELISA. The sgp120 constructs
expressed from 450 to 800 ng/ml, whereas the 3C3d fusions expressed from 140 to 250 ng/ml.
Approximately 90% of the Env protein was present in the supernatant for both sgp120 and
sgp120-3C3d-DNA-transfected cells (data not shown). The approximately 2-fold differences
in the levels of expression of the different sgp120s are likely a reflection in differences in the
Env genes as well as differences in the efficiency that the capture and detection antibodies
recognized the different Envs.
Western blot analyses revealed sgp120 and sgp120-3C3d proteins of the expected sizes (Fig.
2). Using human patient polyclonal antisera, Western blot analysis showed the expected broad
band of 115-120 kDa corresponding to gp120 (Fig. 2). A higher molecular weight band at
ᙺ240 kDa is consistent with the projected size of the sgp120-3C3d fusion protein (Fig. 2).
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Consistent with the antigen-capture assay (Table 1), intense protein bands were present in the
supernatants of cells transfected with sgp120-DNA, whereas less intense bands were present
in the supernatants of cells transfected with sgp120-3C3d-DNA (data not shown). No evidence
for the proteolytic cleavage of the sgp120-C3d fusion protein was seen by Western analysis.
Antibody response to Env gp120-DNA immunizations
The sgp120-3C3d-expressing DNA plasmids raised higher titers of ELISA antibody than the
sgp120 DNA (Fig. 3A). BALB/c mice were vaccinated by DNA-coated gold particles via gene
gun with a 1 ?g dose inoculum. Mice were vaccinated at Day 1 and then boosted at 4, 14, and
26 weeks with the same DNA given in the first immunization. When sera were assayed on
gp120-IIIB-coated plates, mice vaccinated with the DNAs expressing the C3d fusion proteins
had anti-Env antibodies three to seven times higher then the amount of antibody raised by the
counterpart sgp120-expressing plasmids (Fig. 3A). Among the C3d constructs, mice
vaccinated with sgp120-(IIIB)-3C3d had the highest levels of antibody and mice vaccinated
with sgp120-(ADA)-3C3d expressing DNA had the lowest levels of anti-Env antibodies. The
temporal pattern for the appearance of anti-Env antibody revealed titers being boosted at each
of the inoculations for all constructs tested.
Differences in the levels of the antibody raised by the different Envs appeared to be determined
by the specificity of the raised antibody (Fig. 3B). Using an alternative ELISA protocol, in
which antibody was captured on the homologous Env, all of the C3d fusions appeared to raise
similar levels of antibody. In this assay, sheep anti-Env antibody was used to capture transiently
produced sgp120 proteins. This assay revealed low, but similar levels of antibody raised by
each of the sgp120-3C3d constructs. The lower levels of antibody detected in this assay are
likely to reflect the levels of transfection-produced Env used to capture antibody being lower
than in the assays using commercially produced IIIB gp120 to coat plates. As expected using
either ELISA method, booster immunizations were necessary to achieve even the most modest
antibody response.
Avidity of mouse Env antiserum
Sodium thiocyanate (NaSCN) displacement ELISAs demonstrated that the avidity of the
antibody generated with sgp120-3C3d-expressing DNA was consistently higher than that from
sgp120-DNA-vaccinated mice (Fig. 4). Avidity assays were conducted on sera raised by
sgp120-(IIIB) and sgp120-(IIIB-3C3d because of the type specificity of the raised antisera and
the commercial availability of the IIIB protein, but not the other proteins, for use as capture
antigen. The avidity of specific antibodies to Env was compared by using graded concentrations
NaSCN, a chaotropic agent, to disrupt antigen-antibody interaction.24 The binding of
antibodies with less avidity to the antigen is disrupted at lower concentrations of NaSCN than
that of antibodies with greater avidity to the antigen. The effective concentration of NaSCN
required to release 50% of antiserum (ED50) collected at 28 weeks, after four inoculations of
the sgp120-(IIIB)-3C3d-DNA vaccine, was ᙺ2.0 M (Fig. 4). At this time, the avidity for the
gp120-raised sera that could be tested was less than 1. These results indicate that the antibody
from sgp120-(IIIB)-3C3d DNA-vaccinated mice had undergone more rapid affinity maturation
than antibody from sgp120-DNA-vaccinated mice.
Env-3C3d expressing plasmids elicit modest neutralizing antibody
Neutralizing antibody studies performed on MT-2 cells detected higher titers of neutralizing
activity in the sera generated by the gp120-3C3d constructs than in the sera generated by the
sgp120 constructs. (Table 2). Sera were tested against two syncytium-inducing viruses, IIIB
(X4) and 89.6 (X4R5). Mice vaccinated with sgp120-3C3d-expressing plasmids had very
modest levels of neutralizing antibody to the homologous strain of HIV tested by the protection
of MT-2 cells from virus-induced killing as measured by neutral red uptake (Table 2). Titers
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of neutralizing antibody raised by the gp120-expressing DNAs were at the background of the
assay.
DISCUSSION
In this study, we showed that fusions of HIV-1 Env to three copies of murine C3d enhanced
the antibody response to Env in vaccinated mice. Mice vaccinated with any of the three DNA
plasmids expressing the sgp120 sequence had low or undetectable levels of antibody after four
vaccinations (28 weeks postprime). In contrast, mice vaccinated with DNA expressing the
fusion of sgp120 and 3C3d proteins elicited a faster onset of antibody (three vaccinations), as
well as higher levels of antibodies (Fig. 3). C3d is likely to have supported the height of
antibody responses by directly stimulating antibody-producing B cells through complement
receptor 2 (CD21) and expanding the pool of anti-Env-specific B cells.25,26 CD21 is
complexed with the costimulator CD19 on B cells.27,28 Differences in the titers of antibody
elicited by different Envs appeared to reflect the type specificity of the raised antibody. This
was shown by the sera having overall similar titers of antibody when assayed against the
homologous Env (Fig. 3b).
Immunization with the C3d fusions also resulted in enhanced avidity maturation of anti-Env
antibody. Env is a heavily glycosylated protein that may allow it to resemble a T cell-
independent antigen.29 The formation of germinal centers, which are critical for antibody
maturation, could be impeded by the glycosylation of Env.30,31 Previous studies have
described the lengthy evolution of antibody responses to a variety of lentivirus infections.17,
32 Antibodies gradually mature over a 6- to 8-month period from low avidity to reach a steady-
state level of intermediate to high avidity.17,32 Avidity maturation occurs in germinal centers
where the somatic hypermutation of immunoglobulin results in a large repertoire of Ag-specific
B cells that undergo selection for high-affinity B cell receptors. The more rapid avidity
maturation of antibodies elicited by the sgp120-3C3d fusions is consistent with C3d supporting
the entry of B cells producing anti-Env antibody into germinal centers. This could reflect the
C3d domain of the fusion proteins binding to CD21 on follicular dendritic cells and promoting
the entry of B cells recognizing gp120 into a germinal center reaction. Prior studies on the
avidity of DNA-raised anti-Env antibodies have also revealed low-avidity anti-Env antibodies.
16
In contrast to the enhancement of antibody titers and avidity maturation of antibodies to Env,
the amount of neutralizing antibody elicited in the vaccinated mice was low. Mice vaccinated
with plasmids expressing sgp120 had low levels of neutralizing antibody that were only
modestly increased in mice vaccinated with sp120-3C3d-expressing plasmids. However, the
disappointing levels of neutralizing antibodies did seem to increase after the fourth
immunization (Table 2). The poor titers of neutralizing antibody could have reflected an
inherent poor ability of the sgp120-3C3d fusion protein to raise neutralizing antibody because
of the failure to adequately expose neutralizing epitopes to responding B cells. The intrinsic
high backgrounds for HIV-1 neutralization assays in mouse sera may have contributed to the
poor neutralization titers. Also, the correlation between avidity maturation and neutralizing
antibody production to gp120 has not always been clear. Some studies have indicated a good
correlation,17,32,33 whereas others have not.29,34-37 Binley et al.29 demonstrated that
avidity assays, based upon elution of antibody in an in vitro assay for monitoring the antibody
response to HIV-1 gp120 during either vaccination with subunit proteins or natural infection,
did not show a strong correlation between the avidity of the antibody response and the ability
of these same antibodies to neutralize virus.
Much effort is being made to improve the efficacy of HIV vaccines. The approach we tried in
this study was the use of C3d fusion proteins to increase the humoral immune response to the
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envelope protein of HIV. The results demonstrate the effectiveness of C3d fusions as a
molecular adjuvant in enhancing antibody production and enhancing antibody maturation.
However, the neutralizing antibody response to Env was poor and increased slightly in mice
vaccinated with C3d fusion vaccines. Similar to results seen in our previous study using
secreted versions of HA from influenza virus,19 C3d-enhanced antibody responses were
achieved with plasmids expressing only half as much protein as plasmids expressing nonfused
sgp120 (Table 1). In contrast to the present study, virus neutralization titers were dramatically
increased in mice vaccinated with C3d fusion constructs and may have been a result of the low
glycosylation state of HA. These results underscore the importance of increasing our
understanding of the relationship between innate and acquired immunity. They also underscore
the importance of identifying forms of Env that when coupled with C3d are capable of raising
neutralizing antibody. If this can be accomplished, C3d fusions could have a major impact on
the development of the neutralizing component for an AIDS vaccine.
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Schematic representation of vector DNA vaccine constructs. (A) The pGA vector contains the
cytomegalovirus immediate-early promoter (CMV-IE) plus intron A (IA) for initiating
transcription of eukaryotic inserts and the bovine growth hormone polyadenylation terminator
[BGH poly(A)] for termination of transcription. The vector also contains the Col E1 origin of
replication for prokaryotic replication as well as the kanamycin resistance (Kanr) gene for
selection in antibiotic media. The lambda T0 terminator has been placed 3? to the Kanr to
increase the stability of eukaryotic inserts. Inserts were cloned into the vector using the
HindIII and BamHI restriction endonuclease sites. (B) The top schematic represents the wild-
type, transmembrane form of the Env protein. The middle schematic represents the secreted
gp120 form of the Env. The bottom schematic represents the sgp120-3C3d construct used as
a vaccine insert. Linkers composed of two repeats of four glycines and a serine {(G4S)2} were
fused at the junctures of HA and C3d and between each C3d repeat.
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Expression of vaccine constructs in vitro. Human embryonic kidney cells, 293T, were
transfected with 2 ?g of each vaccine plasmid. Supernatant was collected and 1.5% of the total
volume was electrophoresed on a 10% polyacrylamide gel. Lane 1: pGA vector; lane 2: sgp120
(ADA)-DNA; lane 3: sgp120-(IIIB)-DNA; lane 4; sgp120-(89.6)-DNA; lane 5: sgp120-
(ADA)-3C3d-DNA; lane 6: sgp120-(IIIB)-3C3d-DNA; lane 7: sgp120-(89.6)-3C3d-DNA.
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Anti-Env IgG raised by gene gun inoculation of DNAs expressing sgp120 proteins. Mice were
primed at Day 0 and boosted at Weeks 4, 14, and 26. Sera were obtained from mice with vector
(X), sgp120 (ADA)-DNA (?), sgp120-(IIIB)-DNA (?), sgp120-(89.6)-DNA (ᦧ), sgp120-
(ADA)-3 C3d-DNA (?), sgp120-(IIIB)-3C3d-DNA (•), and sgp120-(89.6)-3C3d-DNA (?).
Sera collected at the indicated times from each group were pooled for determination of specific
IgG levels by ELISA at a dilution of 1:100 via two different ELISA protocols. (A) 96-well
plates were coated with recombinant gp120 protein-derived Chinese hamster ovary (CHO)
cells expressing the HIV-1 isolate, IIIB. (B) 96-well plates were coated with supernatant
containing sgp120s from 293T cells that were transiently transfected with sgp120 expression
plasmids. Each ELISA plate was coated with the respective Env to detect antibodies from mice
vaccinated with that particular sgp120, i.e., plates were coated with the ADA-Env in order to
detect antibodies to Env in mice vaccinated with plasmids expressing sgp120-ADA proteins.
Data are represented as the average of three individual assays. Preimmune sera from mice had
no detectable specific IgG. End point dilution titers were conducted by diluting the sera until
OD values reached background.
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Avidity of the anti-Env IgG raised by the IIIB Env-DNA vaccines. Sera were analyzed from
Week 28 in an Env-specific NaSCN-displacement ELISA. Plates were with recombinant
gp120-(IIIB). Sera were obtained from mice immunized with sgp120-(IIIB)-DNA (?) and
sgp120-(IIIB)-3C3d-DNA (•). Assays used pooled serum samples from each mouse group at
a dilution of 1:50 for sgp120-(IIIB) and 1:200 for sgp120-(IIIB)-3C3d. Data are representative
of two independent experiments.
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Table 1.
IN VITRO EXPRESSION LEVELS OF ENV VACCINE PLASMIDS
Env Coreceptor sgp120 sgp120-3C3d Ratioa
IIIB X4 800 175 4.5
89.6 R5X4 600 250 2.4
ADA R5 450 140 3.2
a
Ratio is expressed as the amount of Env protein detected in the supernatant of 293T cells transfected with sgp120 expressing DNA over the amount of
protein detected in supernatant of cells expressing the sgp120-3C3d-expressing constructs.
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TABLE 2.
NEUTRALIZATION ANTIBODY TITER
Vaccine group HIV-1 IIIBa SHIV 89.6a
Week 16
ᒚIIIB gp 120 1:87 NTb
ᒚIIIB gp 120-3C3d 1:178 NT
ᒚ89.6 gp 120 NT 1:38
ᒚ89.6 gp 120-3C3d NT 1:86
Week 28
ᒚIIIB gp 120 1:94 NTb
ᒚIIIB gp 120-3C3d 1:167 NT
ᒚ89.6 gp 120 NT 1:48
ᒚ89.6 gp 120-3C3d NT 1:84
Vector 1:61 1:58
a
Titers are the sample dilution at which 50% of MT-2 cells were protected from virus-induced killing as measured by neutral red uptake.
b
NT, not tested.
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